60 Degrees eyes H2 2026 tafenoquine data as its babesiosis sNDA basis
A 40-patient chronic babesiosis trial and two sister studies are the evidence base for a planned tafenoquine filing, but the pivotal study's own completion date runs past the window.
Executive Summary
- 60 Degrees Pharmaceuticals is building its case for a tafenoquine babesiosis filing on three linked studies rather than a single pivotal trial, and it has told investors to expect supportive data in the second half of 2026.
- The smallest and earliest-reporting of the three studies, an expanded-access program for patients who failed conventional treatment, has produced a clean early signal using the most sensitive infection test available, though the sample is tiny.
- The trial most central to the near-term narrative is not designed to finish before the stated readout window closes, which means any H2 2026 data point will likely come from the smaller, earlier-stage studies rather than the flagship trial.
- The company has already asked the FDA for a faster review designation and plans a meeting to discuss filing requirements, steps that shape the process but do not by themselves establish that the clinical data will support approval.
The catalyst
60 Degrees Pharmaceuticals, Inc. has said data from one or more of its three tafenoquine studies in babesiosis, an expanded-access program (NCT06478641), a placebo-controlled Phase 2 trial (NCT06207370), and the B-FREE Chronic Babesiosis Study (NCT06656351), are expected in the second half of 2026 to support a planned supplemental New Drug Application for tafenoquine, sold as ARAKODA. The company submitted a Breakthrough Therapy Designation request to the FDA on October 3, 2025, and plans a Type B meeting (a mid-development FDA discussion) in early 2026 to review filing requirements. No FDA designation has yet been recorded against the program. 6060 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient ...Oct 15, 2025
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What has read out so far
In the expanded-access study, all three enrolled immunosuppressed patients with relapsing babesiosis were reported cured after treatment with tafenoquine combined with atovaquone, confirmed by an FDA-licensed RNA amplification test used for blood donation screening that is at least 100 times more sensitive than standard PCR. That is a 3-patient cohort, not a statistical readout, but it is the only completed result among the three studies so far. The company said the finding is meant to confirm a high cure rate for tafenoquine in immunosuppressed, relapsing babesiosis patients previously reported by Yale researchers in a 2024 publication. NCT06656351+1B-FREE Chronic Babesiosis StudyNCT0665635160 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient ...Oct 15, 2025
The trial doing the heavy lifting
The B-FREE Chronic Babesiosis Study targets 40 adult patients with severe fatigue and laboratory evidence of babesia exposure, using change in general fatigue as its primary endpoint. It is Recruiting, started November 18, 2025, and carries a primary completion date of February 1, 2027, five months past the close of the stated H2-2026 readout window. The trial's registered enrollment target has not changed since its record was first posted, and the operational profile is otherwise stable: two protocol edits on file, no primary-completion-date change, and no post-completion endpoint amendment. NCT06656351B-FREE Chronic Babesiosis StudyNCT06656351
The comparator trial
The third study is a placebo-controlled Phase 2 trial testing oral tafenoquine plus standard of care against placebo plus standard of care in 33 babesiosis patients, and it is also Recruiting with a primary completion date of March 1, 2027. Between the two Recruiting trials and the completed 3-patient expanded-access cohort, the near-term evidence 60 Degrees can report within the stated window is most likely to come from interim or expanded-access data rather than a completed, prespecified primary-endpoint result from either Phase 2 trial. 6060 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient ...Oct 15, 2025
The competitive and regulatory backdrop
No other sponsor currently has an active trial testing a drug for babesiosis; the closest trials found in a broader disease-area search test unrelated mechanisms in different conditions (kidney transplantation, type 2 diabetes) and are not direct comparators. Tafenoquine itself is already FDA-approved twice, as ARAKODA for malaria prophylaxis and as KRINTAFEL (tafenoquine succinate) for malaria radical cure, sponsored respectively by 60 Degrees and GlaxoSmithKline. That approval history makes this a question of whether an already-approved oral antimalarial can be repurposed for a second indication, not a new-molecule safety question, and no validated pharmacological treatment for babesiosis exists against which to benchmark efficacy.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.